| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| VP2 | HOT VP2-A5146 | AAV8 VP2, Recombinant Protein | Adeno-associated virus 8 | E. coli |  | SDS-PAGE | $300.00 20ug |   | |
| VP2 | HOT VP2-A5145 | AAV9 VP2, Recombinant Protein | Adeno-associated virus 9 | E. coli |  | SDS-PAGE | $300.00 20ug | | |
| VP2 | HOT VP2-A5144 | AAV5 VP2, Recombinant Protein | Adeno-associated virus 5 | E. coli |  | SDS-PAGE | $300.00 20ug | | |
| VP2 | AAV2 VP2, Recombinant Protein | Adeno-associated virus 2 | E. coli |  | SDS-PAGE | $310.00 50ug | | ||
| VP2 | AAV6 VP2, Recombinant Protein | Adeno-associated virus 6 | E. coli |  | SDS-PAGE | $300.00 20ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) | Phase 2 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | ||
| CTB-ACE2 | CTB-ACE2 | Phase 2 Clinical | University Of Pennsylvania | Coronavirus Disease 2019 (COVID-19) | Details |
| HH-120 | HH-120 | Phase 2 Clinical | Huahui Health Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| B38-CAP | Phase 1 Clinical | Akita University | Coronavirus Disease 2019 (COVID-19) | Details | |
| 68Ga-labeled ACE2 Targeting Probe(Peking Union Medical College Hospital) | 68Ga-A3 | Phase 1 Clinical | Peking Union Medical College Hospital | Small Cell Lung Carcinoma; Lung Neoplasms | Details |
| AOD01 | AOD01; AOD-01 | Phase 1 Clinical | A*Star | Coronavirus Disease 2019 (COVID-19) | Details |
| SBK-001 | SBK-001 | Phase 1 Clinical | Chengdu Shibeikang Biomedical Technology Co Ltd | Acute Lung Injury | Details |
